Curious whether Medpace Holdings at US$610.90 is starting to look expensive or still offers value? This article walks through ...

In recent months, Medpace Holdings has reported strong organic revenue growth, high return on equity, and long-term earnings expansion from its global clinical research operations across North America ...

What a time it’s been for Medpace. In the past six months alone, the company’s stock price has increased by a massive 96.1%, ...

S&P 500 components BlackRock and GE Aerospace are among the five stocks to watch in next week's shortened stock market action ...

CEO August Troendle noted that Q1 2025 net awards decreased sequentially and year-over-year, resulting in a net book-to-bill ratio of 0.90. He attributed this decline to high pipeline cancellations in ...

Medpace has a strong financial position with high profit margins and low debt, and it has grown at a fast rate in the last five years. The company expects headwinds in 2025 in that it foresees that ...

Total revenue was up 14.6% on a year-over-year basis. Medpace said its backlog increased 13.7% year-over-year to $2.925 billion. The company generated $116.4 million in cash flow during the quarter.

Medpace Hldgs (NASDAQ:MEDP) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Madison Investments, an investment advisor, released its “Madison Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund (Class I ...

Medpace Holdings Inc. (NASDAQ:MEDP) posted better-than-expected third-quarter earnings on Thursday. The clinical contract research organization reported earnings of $3.86, beating the consensus of ...

Whiskey Yard’s whiskey library will feature more than 200 selections, along with handcrafted cocktails. The venue will also include a live piano bar. Protests persist after ICE killing; Cincinnati ...

Medpace recently said it planned to spend $500 million on a stock buyback. The company also upgraded yearly guidance. Medpace does most of its business with smaller pharmaceutical or medical equipment ...